DOCSLIB.ORG

Counselor's Family Education Manual: Matrix Intensive Outpatient Treatment

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Counselor's Family Education Manual: Matrix Intensive Outpatient Treatment Counselor’s Family Education Manual Matrix Intensive Outpatient Treatment for People With Stimulant Use Disorders Please share your thoughts about this publication by completing a brief online survey at: https://www.surveymonkey.com/r/KAPPFS The survey takes about 7 minutes to complete and is anonymous. Your feedback will help SAMHSA develop future products. Counselor’s Family Education Manual Matrix Intensive Outpatient Treatment for People With Stimulant Use Disorders U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Substance Abuse Treatment 1 Choke Cherry Road Rockville, MD 20857 Acknowledgments Numerous people contributed to this document, which is part of the Methamphetamine Treatment Project (MTP). The document was written by Jeanne L. Obert, M.F.T., M.S.M.; Richard A. Rawson, Ph.D.; Michael J. McCann, M.A.; and Walter Ling, M.D. The MTP Corporate Authors provided valuable guidance and support on this document. This publication was developed with support from the University of California at Los Angeles (UCLA) Coordinating Center through Grant No. TI11440. MTP was funded by the Center for Substance Abuse Treatment (CSAT), Substance Abuse and Mental Health Services Administration (SAMHSA), U.S. Department of Health and Human Services (HHS). The research was conducted from 1998 to 2002 in cooperation with the following institutions: County of San Mateo, San Mateo, CA (TI11411); East Bay Recovery Project, Hayward, CA (TI11484); Friends Research Institute, Inc., Concord, CA (TI11425); Friends Research Institute, Inc., Costa Mesa, CA (TI11443); Saint Francis Medical Center of Hawaii, Honolulu, HI (TI11441); San Diego Association of Governments, San Diego, CA (TI11410); South Central Montana Regional Mental Health Center, Billings, MT (TI11427); and UCLA Coordinating Center, Los Angeles, CA (TI11440). The publication was produced by JBS International, Inc. (JBS), under Knowledge Application Program (KAP) contract numbers 270-99-7072 and 270-04-7049 with SAMHSA, HHS. Christina Currier served as the CSAT Government Project Officer. Andrea Kopstein, Ph.D., M.P.H., served as the Deputy Government Project Officer. Cheryl Gallagher, M.A., served as CSAT content advisor. Disclaimer The views, opinions, and content of this publication are those of the authors and do not necessarily reflect the views, opinions, or policies of SAMHSA or HHS. Public Domain Notice All material appearing in this report is in the public domain and may be reproduced or copied without permission from SAMHSA. Citation of the source is appreciated. However, this publication may not be reproduced or distributed for a fee without the specific, written authorization of the Office of Communications, SAMHSA, HHS. Electronic Access and Printed Copies This publication may be ordered or downloaded from SAMHSA’s Publications Ordering Web page at http://store.samhsa.gov. Or, please call SAMHSA at 1-877-SAMHSA-7 (1-877-726-4727) (English and Español). Recommended Citation Center for Substance Abuse Treatment. Counselor’s Family Education Manual: Matrix Intensive Outpatient Treatment for People With Stimulant Use Disorders. HHS Publication No. (SMA) 13-4153. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2006. Originating Office Quality Improvement and Workforce Development Branch, Division of Services Improvement, Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, 1 Choke Cherry Road, Rockville, MD 20857. HHS Publication No. (SMA) 13-4153 First printed 2006 Revised 2007, 2010, 2011, 2012, and 2013 ii Contents I. Introduction to the Matrix Intensive Outpatient Treatment for People With Stimulant Use Disorders Approach and Package ................... 1 Background ................................................................ 1 Matrix IOP Approach ......................................................... 2 The Role of the Counselor .................................................... 5 The Matrix IOP Package ...................................................... 6 Introduction to the Family Education Group ....................................... 7 II. Session Instructions ........................................... 11 Family Education Sessions Overview .......................................... 11 Session 1: Triggers and Cravings (PowerPoint Presentation) ........................ 13 Session 2: Alcohol and Recovery (PowerPoint Presentation) ........................ 21 Session 3: Recovery (Panel Presentation). 30 Session 4: Methamphetamine and Cocaine (PowerPoint Presentation) ................ 31 Session 5: Roadmap for Recovery (PowerPoint Presentation) ....................... 43 Session 6: Coping With the Possibility of a Relapse (Multifamily Group Discussion) ...... 56 Session 7: Opioids and Club Drugs (PowerPoint Presentation). 58 Session 8: Families in Recovery (PowerPoint Presentation) ......................... 67 Session 9: Rebuilding Trust (Multifamily Group Discussion) ......................... 77 Session 10: Marijuana (PowerPoint Presentation). 78 Session 11: Living With an Addiction (Multifamily Group Discussion) .................. 84 Session 12: Communication Traps (Multifamily Group Discussion) .................... 85 III. Family Education Handouts .................................... 89 Appendices Appendix A. The Methamphetamine Treatment Project ............................ 155 Appendix B. Notes on Group Facilitation ....................................... 157 Appendix C. Acronyms and Abbreviations List ................................... 159 Appendix D. Field Reviewers ................................................ 161 Appendix E. Bibliography ................................................... 163 Appendix F. Acknowledgments ............................................... 167 iiiiii This page intentionally left blank. I. Introduction to the Matrix Intensive Outpatient Treatment for People With Stimulant Use Disorders Approach and Package The Matrix Intensive Outpatient Treatment for People With Stimulant Use Disorders (IOP) pack- Background age provides a structured approach for treating The Matrix IOP method was developed initially in adults who abuse or are dependent on stimulant the 1980s in response to the growing numbers drugs. The approach followed in the treatment of individuals entering the treatment system with package was developed by the Matrix Institute in cocaine or methamphetamine dependence as Los Angeles, California, and was adapted for this their primary substance use disorder. Many treatment package by the Knowledge Application traditional treatment models then in use were Program of the Center for Substance Abuse developed primarily to treat alcohol dependence Treatment of the Substance Abuse and Mental and were proving to be relatively ineffective in Health Services Administration (SAMHSA). The treating cocaine and other stimulant dependence Matrix IOP package comprises five components: (Obert et al. 2000). ■ Counselor’s Treatment Manual To create effective treatment protocols for cli- ■ Counselor’s Family Education Manual ents dependent on stimulant drugs, treatment (this document) professionals at the Matrix Institute drew from numerous treatment approaches, incorporating ■ CD-ROM that accompanies the into their model methods that were empirically Counselor’s Family Education Manual tested and practical. Their treatment model ■ Client’s Handbook incorporated elements of relapse prevention, cognitive–behavioral, psychoeducation, and Client’s Treatment Companion ■ family approaches, as well as 12-Step program support (Obert et al. 2000). The Matrix IOP model and this treatment pack- age based on that model grew from a need for The effectiveness of the Matrix IOP approach structured, evidence-based treatment for clients has been evaluated numerous times since its who abuse or are dependent on stimulant drugs, inception (Rawson et al. 1995; Shoptaw et al. particularly methamphetamine and cocaine. This 1994). SAMHSA found the results of these stud- comprehensive package provides substance ies promising enough to warrant further evalua- abuse treatment professionals with a yearlong tion (e.g., Obert et al. 2000; Rawson et al. 2004). intensive outpatient treatment model for these clients and their families: 16 weeks of structured In 1998, SAMHSA initiated a multisite study of programming and 36 weeks of continuing care. treatments for methamphetamine dependence 1 Counselor’s Family Education Manual: Matrix Intensive Outpatient Treatment and abuse, the Methamphetamine Treatment Clients may begin attending the fifth type of Project (MTP). The study compared the clinical counseling session, continuing care (Social and cost effectiveness of a comprehensive Support groups), once they have completed the treatment model that follows a manual devel- 12-session Family Education group but are still oped by the Matrix Institute with the effective- attending Relapse Prevention group sessions. ness of treatment approaches in use at eight Overlapping Social Support group attendance community-based treatment programs, including with the intensive phase of treatment helps six programs in California, one in Montana, and ensure a smooth transition to continuing care. one in Hawaii. Appendix A provides more infor- mation about MTP. The Matrix IOP method also familiarizes clients with 12-Step programs and other support groups, teaches clients time management and schedul- Matrix IOP Approach ing skills, and entails conducting
Load more

Recommended publications
  • The Ethics of Psychedelic Medicine: a Case for the Reclassification of Psilocybin for Therapeutic Purposes
    THE ETHICS OF PSYCHEDELIC MEDICINE: A CASE FOR THE RECLASSIFICATION OF PSILOCYBIN FOR THERAPEUTIC PURPOSES By Akansh Hans A thesis submitted to Johns Hopkins University in conformity with the requirements for the degree of Master of Bioethics Baltimore, Maryland May 2021 © 2021 Akansh Hans All Rights Reserved I. Abstract Our current therapeutic mental health paradigms have been unable to adequately handle the mental illness crisis we are facing. We ought to ‘use every tool in our toolbox’ to help individuals heal, and the tool we should be utilizing right now is Psilocybin. Although it is classified as a Schedule I drug, meaning that it is believed to have a high potential for abuse, no accepted medical uses, and a lack of safety when used under medical supervision, Psilocybin is not addictive and does not have a high potential for abuse when used safely under medical supervision. For these reasons alone, Psilocybin deserves a reclassification for therapeutic purposes. However, many individuals oppose Psilocybin-assisted psychotherapy on ethical grounds or due to societal concerns. These concerns include: a potential change in personal identity, a potential loss of human autonomy, issues of informed consent, safety, implications of potential increased recreational use, and distributive justice and fairness issues. Decriminalization, which is distinct from reclassification, means that individuals should not be incarcerated for the use of such plant medicines. This must happen first to stop racial and societal injustices from continuing as there are no inherently ‘good’ or ‘bad’ drugs. Rather, these substances are simply chemicals that humans have developed relationships with. As is shown in this thesis, the ethical implications and risks of psychedelic medicine can be adequately addressed and balanced, and the benefits of Psilocybin as a healing tool far outweigh the risks.
    [Show full text]
  • Hallucinogens
    Hallucinogens What Are Hallucinogens? Hallucinogens are a diverse group of drugs that alter a person’s awareness of their surroundings as well as their thoughts and feelings. They are commonly split into two categories: classic hallucinogens (such as LSD) and dissociative drugs (such as PCP). Both types of hallucinogens can cause hallucinations, or sensations and images that seem real though they are not. Additionally, dissociative drugs can cause users to feel out of control or disconnected from their body and environment. Some hallucinogens are extracted from plants or mushrooms, and others are synthetic (human-made). Historically, people have used hallucinogens for religious or healing rituals. More recently, people report using these drugs for social or recreational purposes. Hallucinogens are a Types of Hallucinogens diverse group of drugs Classic Hallucinogens that alter perception, LSD (D-lysergic acid diethylamide) is one of the most powerful mind- thoughts, and feelings. altering chemicals. It is a clear or white odorless material made from lysergic acid, which is found in a fungus that grows on rye and other Hallucinogens are split grains. into two categories: Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) comes from certain classic hallucinogens and types of mushrooms found in tropical and subtropical regions of South dissociative drugs. America, Mexico, and the United States. Peyote (mescaline) is a small, spineless cactus with mescaline as its main People use hallucinogens ingredient. Peyote can also be synthetic. in a wide variety of ways DMT (N,N-dimethyltryptamine) is a powerful chemical found naturally in some Amazonian plants. People can also make DMT in a lab.
    [Show full text]
  • Online Can You Make Methamphetamine from Adderall
    dx icd 10 for hip fracture | bible bingo | comcast box hack | hack slot machines electronic devices | Home Can you make methamphetamine from adderall . Company Can you make methamphetamine from adderall Home How to Get Adderall Out of Your System. Avoiding Relapse: Tips For Taking Your Mind Baptist bylaws for Off Cravings. Center for Substance Abuse Research. (n.d.). Amphetamines. Retrieved black baptist from. The second reaction (below) is quite different. Phenylephrine contains two church different hydroxyl (OH) groups, as shown in the blue and green circles. But the How can you play hydroxyl group in the blue circle (called a phenolic group) is chemically unreactive. So minecraft when if you react phenylephrine with phosphorous and iodine it only the OH in the green school blocks it circle is affected. The product of this reaction is 3-(2-aminopropyl)phenol, (aka Brown discharge gepefrin), which is a mediocre blood pressure drug sold in Europe. It won't make you 24 weeks high. However, high amphetamine doses that are above the therapeutic range can pregnant interfere with working memory and other aspects of cognitive control. [10]. Their Dell recycling mechanisms of action vary, but each has a profound impact on memory, mood, and return label mental energy. Many of these substances are also popular herbal remedies for the Office 2010 on treatment of ADHD. Studies prove they can reduce the likelihood of developing sale neurodegenerative diseases as well. Caffeine is not an herb, but it deserves mention since it derives from herbal teas and coffee beans. Caffeine is a natural stimulant that improves brain power and energy levels.
    [Show full text]
  • Adverse Reactions to Hallucinogenic Drugs. 1Rnstttutton National Test
    DOCUMENT RESUME ED 034 696 SE 007 743 AUTROP Meyer, Roger E. , Fd. TITLE Adverse Reactions to Hallucinogenic Drugs. 1rNSTTTUTTON National Test. of Mental Health (DHEW), Bethesda, Md. PUB DATP Sep 67 NOTE 118p.; Conference held at the National Institute of Mental Health, Chevy Chase, Maryland, September 29, 1967 AVATLABLE FROM Superintendent of Documents, Government Printing Office, Washington, D. C. 20402 ($1.25). FDPS PRICE FDPS Price MFc0.50 HC Not Available from EDRS. DESCPTPTOPS Conference Reports, *Drug Abuse, Health Education, *Lysergic Acid Diethylamide, *Medical Research, *Mental Health IDENTIFIEPS Hallucinogenic Drugs ABSTPACT This reports a conference of psychologists, psychiatrists, geneticists and others concerned with the biological and psychological effects of lysergic acid diethylamide and other hallucinogenic drugs. Clinical data are presented on adverse drug reactions. The difficulty of determining the causes of adverse reactions is discussed, as are different methods of therapy. Data are also presented on the psychological and physiolcgical effects of L.S.D. given as a treatment under controlled medical conditions. Possible genetic effects of L.S.D. and other drugs are discussed on the basis of data from laboratory animals and humans. Also discussed are needs for futher research. The necessity to aviod scare techniques in disseminating information about drugs is emphasized. An aprentlix includes seven background papers reprinted from professional journals, and a bibliography of current articles on the possible genetic effects of drugs. (EB) National Clearinghouse for Mental Health Information VA-w. Alb alb !bAm I.S. MOMS Of NAM MON tMAN IONE Of NMI 105 NUNN NU IN WINES UAWAS RCM NIN 01 NUN N ONMININI 01011110 0.
    [Show full text]
  • DEMAND REDUCTION a Glossary of Terms
    UNITED NATIONS PUBLICATION Sales No. E.00.XI.9 ISBN: 92-1-148129-5 ACKNOWLEDGEMENTS This document was prepared by the: United Nations International Drug Control Programme (UNDCP), Vienna, Austria, in consultation with the Commonwealth of Health and Aged Care, Australia, and the informal international reference group. ii Contents Page Foreword . xi Demand reduction: A glossary of terms . 1 Abstinence . 1 Abuse . 1 Abuse liability . 2 Action research . 2 Addiction, addict . 2 Administration (method of) . 3 Adverse drug reaction . 4 Advice services . 4 Advocacy . 4 Agonist . 4 AIDS . 5 Al-Anon . 5 Alcohol . 5 Alcoholics Anonymous (AA) . 6 Alternatives to drug use . 6 Amfetamine . 6 Amotivational syndrome . 6 Amphetamine . 6 Amyl nitrate . 8 Analgesic . 8 iii Page Antagonist . 8 Anti-anxiety drug . 8 Antidepressant . 8 Backloading . 9 Bad trip . 9 Barbiturate . 9 Benzodiazepine . 10 Blood-borne virus . 10 Brief intervention . 11 Buprenorphine . 11 Caffeine . 12 Cannabis . 12 Chasing . 13 Cocaine . 13 Coca leaves . 14 Coca paste . 14 Cold turkey . 14 Community empowerment . 15 Co-morbidity . 15 Comprehensive Multidisciplinary Outline of Future Activities in Drug Abuse Control (CMO) . 15 Controlled substance . 15 Counselling and psychotherapy . 16 Court diversion . 16 Crash . 16 Cross-dependence . 17 Cross-tolerance . 17 Custody diversion . 17 Dance drug . 18 Decriminalization or depenalization . 18 Demand . 18 iv Page Demand reduction . 19 Dependence, dependence syndrome . 19 Dependence liability . 20 Depressant . 20 Designer drug . 20 Detoxification . 20 Diacetylmorphine/Diamorphine . 21 Diuretic . 21 Drug . 21 Drug abuse . 22 Drug abuse-related harm . 22 Drug abuse-related problem . 22 Drug policy . 23 Drug seeking . 23 Drug substitution . 23 Drug testing . 24 Drug use .
    [Show full text]
  • Hallucinogens
    Hallucinogens What are hallucinogens? Hallucinogens are a diverse group of drugs that alter a person’s awareness of their surroundings as well as their own thoughts and feelings. They are commonly split into two categories: classic hallucinogens (such as LSD) and dissociative drugs (such as PCP). Both types of hallucinogens can cause hallucinations, or sensations and images that seem real though they are not. Additionally, dissociative drugs can cause users to feel out of control or disconnected from their body and environment. Some hallucinogens are extracted from plants or mushrooms, and some are synthetic (human- made). Historically, people have used hallucinogens for religious or healing rituals. More recently, people report using these drugs for social or recreational purposes, including to have fun, deal with stress, have spiritual experiences, or just to feel different. Common classic hallucinogens include the following: • LSD (D-lysergic acid diethylamide) is one of the most powerful mind-altering chemicals. It is a clear or white odorless material made from lysergic acid, which is found in a fungus that grows on rye and other grains. LSD has many other street names, including acid, blotter acid, dots, and mellow yellow. • Psilocybin (4-phosphoryloxy-N,N- dimethyltryptamine) comes from certain types of mushrooms found in tropical and subtropical regions of South America, Mexico, and the United States. Some common names for Blotter sheet of LSD-soaked paper squares that users psilocybin include little smoke, magic put in their mouths. mushrooms, and shrooms. Photo by © DEA • Peyote (mescaline) is a small, spineless cactus with mescaline as its main ingredient. Peyote can also be synthetic.
    [Show full text]
  • The Entheogen Review , Pob 19820, Sa Cramento , Ca 95819-0820, Usa  161 Vol Ume X, Number 4 Winter Solstice 2001
    VOL UME X, NUMBER 4 WINTER SOLSTICE 2001 Index Symbols Age of Entheogens & The Angels’ Dictionary, Analog Act 84, 85 The 154 Anand, Margot 67, 154 ∞Ayes 32, 49, 50, 51 age regression 89 Anderson, E.F. 106 1,4-butanediol 84 Aguaruna Indians 10 Anderson, Rocky 41 1984 155 Aguirre, G., L.E. 3, 5, 6 Anderson, Sherry 156 2001 52 Agurell, S. 57, 58, 106 Andrews, S. 86 2C-B 22, 28, 118 ahpí 7 anesthetize 21 2C-D 20 ajucá 6 angico 6 2C-I 20 Akashic record 54 angicos brancos 6 2C-T-2 20, 22, 90 Al-Queda terrorists 123 angicos pretos 6 2C-T-4 20 Alarcón, R. 5 angiquín 6 2C-T-7 20, 85, 89, 90, 94, 105, 114 Alchemind Society, The 42, 76, 112 angiquinho 6 4-acetoxy-DET 88, 89, 90, 92, 93, 96 alcohol Angraecum fragrans 86 4-acetoxy-DIPT 29, 30, 88, 90, 91, 93 38, 52, 74, 84, 98, 99, 134, 145, 146 Anon. 151 4-hydroxy-αMT 139 alcoholic beverages 86 anonymous remailer 123 4-hydroxy-DET 88, 89, 139 Aldrich 83 anthraquinones 86 4-hydroxy-DMT 88 alfalfa 129 anti-cholinergic-like central effect 150 4-hydroxy-DPT 139 alien 32, 50, 53 anti-depressant 28 5-MeO-αMT 148 alien robots 52 anti-inflammatory 86 5-MeO-DIPT 90, 94 AllChemical Arts (conference) 115 anti-marijuana laws 46 5-MeO-DMT Allen, John W. 112 anti-nausea medications 28 1, 5, 25, 84, 89, 99, 101, 102, 103, allergy preparations 28 antibacterial 135 118, 126, 148 Alli, Antero 114 antibiotic 28 5-methoxytryptamine 150 Allison 156 antidiarrheal 104 Alpert, Richard 34 antispasmatic 28 A alpha 140, 141, 142, 143, 144, 145 Antonil, André João 4 Aardvark, David α-MT 148 ants 151 α 21, 27, 28, 30, 34, 51,
    [Show full text]
  • Meth and Oral Health a Guide for Dental Professionals Hazelden Center City, Minnesota 55012-0176 1-800-328-9000 1-651-213-4590 (Fax)
    METH ORAL HEALTH A GUIDE FOR DENTAL PROFESSIONALS Meth and Oral Health A Guide for Dental Professionals Hazelden Center City, Minnesota 55012-0176 1-800-328-9000 1-651-213-4590 (fax) www.hazelden.org ©2007 by Hazelden Foundation All rights reserved. Published 2007 Printed in the United States of America Duplicating this guide is not permissible. The handouts on pages 15–16 and 17 may be duplicated for professional use, but may not be sold or repurposed for other uses without the permission of the publisher. To request permission, write to Permissions Coordinator, Hazelden, P.O. Box 176, Center City, MN 55012-0176. The material in this guide can help dental professionals provide dental treatment to users of methampheta- mine (meth) and educate staff and patients about the dangers of meth use. However, this information is not meant to override any state law or the medical and legal advice of any state dental board. The reader should consult the guidelines, regulations, and laws in his or her state on matters relating to a patient’s health. This guide focuses on the clinical implications of meth use and does not address whether an individual’s health or benefit plan(s) cover or provide benefit for the clinical services mentioned in this document. Web addresses cited in this guide are accurate as of press time, but are subject to change. Cover design by Terry Kriebech, DeCare International Interior design by David Spohn Typesetting by Tursso Companies Photographs courtesy of Charles Tatlock, D.D.S. Introduction: About This Guide This guide presents the latest information about methamphetamine (meth) use and its effects on oral health.
    [Show full text]
  • Meth Myths & Facts
    Meth Myths & Facts: What Science Tells Us New or resurging drug trends often spark what scientists have christened a drug panic. During such drug panics, professional and public proclamations about the drug and those who consume it are often highly inaccurate. One of the most recent of such panics involves the drug methamphetamine. Below is listed some of the myths about methamphetamine and what scientific studies have subsequently confirmed. Myth or Fact? Methamphetamine is America’s number one drug problem and its use is on the rise, particularly among teens. The Science: Only 600,000 Americans used methamphetamine in the past month compared to a total of 19.2 million who consumed some illicit drug and half of Americans over age 12 who reported past month alcohol consumption (SAMHSA, 2005). The prevalence of past month methamphetamine consumption among 12-17 year olds is declining, with its current level at 0.7 percent (SAMHSA, 2004; Johnston, et al, 2005). Myth or Fact? Meth is instantly addictive. The Science: It generally takes 2 to 5 years to establish methamphetamine dependence (SAMHSA, 1999). Myth or Fact? Methamphetamine is now the primary drug of choice for those admitted to addiction treatment in the United States. The Science? Methamphetamine is identified as a primary or secondary drug among only 12% of those entering addiction treatment in the Unites States (DASIS Report, 2006). Myth or Fact? Recovering from methamphetamine dependence takes longer than does recovery from other drug dependencies. The Science: There is a longer trajectory of recovery from the physical emaciation and adverse psychological effects from methamphetamine dependence than is the case with other drug dependencies (Cretzmeyer, Sarrazin, Huber, et al, 2003) Myth or Fact? Addiction treatment is not effective for meth addicts? The Science: Treatment follow-up studies of individuals treated for methamphetamine dependence reveal outcomes reveal outcomes comparable to those treated for heroin of cocaine dependence.
    [Show full text]
  • City of West Hollywood Substance Abuse Services Guide City of West Hollywood Substance Abuse Services Guide
    CITY OF WEST HOLLYWOOD SUBSTANCE ABUSE SERVICES GUIDE CITY OF WEST HOLLYWOOD SUBSTANCE ABUSE SERVICES GUIDE APLA HEALTH CHILDREN’S HOSPITAL - MCINTYRE HOUSE TWIN TOWN TREATMENT (213) 201-1600 SUBSTANCE USE PREVENTION (323) 662-0855 CENTERS www.aplahealth.org & TREATMENT PROGRAM www.mcintyrehouse.org (866) 594-8844 Health services, HIV support (323) 361-2463 McIntyre House offers a residential www.twintowntreatmentcenters.com services, and prevention/health www.chla.org/substance-abuse- rehabilitative experience for men Offers six intensive outpatient education for people living with prevention-and-treatment-services seeking recovery from alcoholism and treatment programs for adult and and affected by HIV, the LGBT A state-certified program that aims drug addiction. adolescent addictions in Los Angeles community, and other underserved to reduce alcohol and drug-related and Orange County (including West communities. Party Wise Crystal harm in an outpatient approach. The TARZANA TREATMENT Hollywood location). Accepts most Methamphetamine Program program serves youth ages 10-17 and CENTERS insurance plans and/or flex payment offers risk-reduction trainings, young adults ages 18-25 by offering (888)777-8565 schedules. support groups and community education and support to their www.tarzanatc.org events for gay men who use families and significant others. Provides inpatient medical VAN NESS RECOVERY methamphetamine. For more detoxification and psychiatric HOUSE information contact Roger Sediles FRIENDS COMMUNITY CENTER stabilization, residential
    [Show full text]
  • Methamphetamine and Other Potentially Risky Sex-Enhancing Drugs
    METHAMPHETAMINE AND OTHER POTENTIALLY RISKY SEX-ENHANCING DRUGS A DISSERTATION SUBMITTED TO THE FACULTY OF THE AMERICAN ACADEMY OF CLINICAL SEXOLOGISTS AT MAIMONIDES UNIVERSITY IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY BY DAVID MICHAEL FAWCETT ALFREDO EUGENIO TAULE' NORTH MIAMI BEACH, FLORIDA DECEMBER, 2004 DISSERTATION APPROVAL This dissertation submitted by David Michael Fawcett and Alfredo Eugenio Taule' has been read and approved by three faculty members of the American Academy of Clinical Sexologists at Maimonides University. The final copies have been examined by the Dissertation Committee and the signatures which appear here verify the fact that any necessary changes have been incorporated and the dissertation is now given the final approval with reference to content, form and mechanical accuracy. The dissertation is therefore accepted in partial fulfillment of the requirements for the degree of Doctor of Philosophy. Signature Date ______________________________ ______________ William Granzig, Ph.D., FAACS Advisor and Committee Chair ______________________________ _______________ John Achinapura, Ph.D. Committee Member ______________________________ _______________ James Walker, Ph.D. Committee Member ii ACKNOWLEDGEMENTS I dedicate this dissertation to my first born son Timothy who at the age of thirty-four after the terrorist attack in New York and Washington became a part of our proud military forces. At present he is a proud Airborne Ranger protecting our nation in a dangerous forward zone in the Sunni Triangle in Iraq. Timothy's resolve and courage as well as all of his accomplishments in such a short period of time have become a great source of inspiration for our family. My son has become my hero and he has made me aware of noble feelings like honor, loyalty, patriotism and commitment.
    [Show full text]
  • Hallucinogens Hallucinations
    Hallucinogens Hallucinations Affect a person’s: Perceptions Sensations Thinking Self-awareness Emotional state Synesthesia Transposition of senses: Seeing sounds Hearing colors Flash Back Vivid recollection of hallucinogenic experience Emotional “Bad trip” (Panic, fear, etc.) Somatic Altered body sensations, tremors, weakness, dizziness, crawly, tingling feeling on the skin Perceptual Distortions of the five senses Psychotomimetic Something that mimics psychosis Delusion A false belief Illusion A false perception Natural Hallucinogens Peyote (Mescaline) Psilocybin Natural Hallucinogens Jimson Weed Bufo Alvarius Natural Hallucinogens Morning Glory Seeds Nutmeg Natural Hallucinogens Salvia Divinorum Synthetic Hallucinogens LSD (Lysergic Acid Diethylamide) MDMA “Ecstasy” (3, 4 Methylenedioxymethamphetamine) Methods of Ingestion Orally Smoked Transdermal Insufflation Injection General Indicators Varies and influenced by personality, mood, expectations and surroundings of user Depressed = deeper depression Pleasant = heightened pleasure Can uncover emotional flaws Bad “trip” Effects Hallucinations Body tremors Paranoia Uncoordinated Nausea Disoriented Perspiring Memory loss Difficulty in speech Flashbacks Synesthesia Poor time perception Dazed appearance Onset and Duration - Peyote 30 minutes: Onset Nausea, elevated blood pressure, pulse and temperature and dilated pupils 60 minutes: Begin hallucinogenic effects Visual distortions, rich colors, changing forms and moving shapes 3-4 hours: Peak effects “Synesthesia”
    [Show full text]